Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib + Paclitaxel in Recurrent Ovarian Cancer
NCT01204749Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2010
- Primary completion
- Mar 2013
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 32
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Trebananib + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Progression-Free Survival at 8 months. Started Nov 2010; status: completed.
02
Drugs
trebananib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT01204749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204749.